What is Recursion?
Recursion operates at the vanguard of the biotechnology industry, utilizing its proprietary Recursion Operating System to decode complex biological and chemical datasets. By synthesizing machine learning, engineering, and automation, the company aims to transcend traditional drug discovery limitations. The firm's core value proposition lies in its ability to navigate foundational biology without the constraints of human bias, effectively mapping new therapeutic pathways. This data-centric methodology allows Recursion to accelerate the development of novel treatments, positioning it as a critical player in the future of pharmaceutical research and development.
How much funding has Recursion raised?
Recursion has raised a total of $514.5M across 10 funding rounds:
Multiple Rounds
$4.9M
Series A
$15M
Debt
$4M
Series B
$60M
Other Financing Round
$20.5M
Series C
$121M
Series D
$239M
Other Financing Round
$50M
Debt (2015): $830K, investors not publicly disclosed
Unspecified (2015): $1.5M led by National Institutes of Health
Angel/Seed (2015): $2.6M supported by Advantage Capital Partners
Series A (2016): $15M featuring AME Cloud Ventures, Data Collective, Lux Capital, Obvious Ventures, Wild Basin Investments, and Epic Ventures
Debt (2017): $4M backed by Square 1 Bank
Series B (2017): $60M with participation from Data Collective
Other Financing Round (2018): $20.5M led by Square 1 Bank
Series C (2019): $121M supported by Obvious Ventures, Mubadala Ventures, Intermountain Ventures, Felicis Ventures, Data Collective, Texas Tech University System, Menlo Ventures, Lux Capital, Two Sigma Ventures, Epic Ventures, CRV, AME Cloud Ventures, and Scottish Mortgage Investment Trust PLC
Series D (2020): $239M featuring Catalio Capital Management, Baillie Gifford International, Advantage Capital, Lux Capital, Mubadala, Felicis Ventures, Laurion Capital Management, DCVC, Two Sigma Ventures, Casdin Capital, Intermountain Ventures, EPIC Ventures, Leaps by Bayer, Samsara BioCapital, and Obvious Ventures
Other Financing Round (2023): $50M backed by NVIDIA
Key Investors in Recursion
NVIDIA
NVIDIA is a global technology leader specializing in graphics processing units and artificial intelligence computing solutions that power high-performance research and machine learning applications.
DCVC
Data Collective is a venture capital firm that invests in deep tech companies, focusing on businesses that leverage data and artificial intelligence to solve complex industrial challenges.
Lux Capital
Lux Capital is a prominent venture firm that specializes in early-stage investments in emerging technologies, particularly those at the intersection of science and engineering.
What's next for Recursion?
With the recent strategic capital injection, Recursion is well-positioned to scale its computational infrastructure and expand its proprietary biological datasets. The company's roadmap focuses on deepening the capabilities of the Recursion Map, further refining its algorithmic tools to identify high-potential drug candidates with greater precision. As the firm transitions into more advanced clinical stages, the focus will likely shift toward strategic partnerships and the industrialization of its discovery pipeline, ensuring that its AI-driven insights translate into tangible patient outcomes. The ongoing support from high-profile technology and venture capital backers provides the necessary runway to sustain this ambitious growth trajectory in the competitive biotech landscape.
See full Recursion company page
